missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD31 Monoclonal Antibody (MBC78.2), FITC

Descripción
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.
CD31 (platelet endothelial cell adhesion molecule-1, PECAM-1) is an inhibitory coreceptor involved in regulation of T cell and B cell signaling by a dual immunoreceptor tyrosine-based inhibitory motif (ITIM) that upon associated kinases-mediated phosphorylation provide docking sites for protein-tyrosine phosphatases. CD31 is expressed ubiquitously within the vascular compartment and is located mainly at junctions between adjacent cells. N-terminal Ig-like domain of CD31 is responsible for its homophilic binding, which plays an important role in cell-cell interactions. CD31 is a multifunctional molecule with diverse roles in modulation of integrin-mediated cell adhesion, transendothelial migration, angiogenesis, apoptosis, negative regulation of immunoreceptor signaling, autoimmunity, macrophage phagocytosis, IgE-mediated anaphylaxis and thrombosis. It is one of key regulatory molecules in vascular system.
Especificaciones
Especificaciones
| Antígeno | CD31 |
| Aplicaciones | Flow Cytometry |
| Clasificación | Monoclonal |
| Clon | MBC78.2 |
| Concentración | 0.2mg/mL |
| Conjugado | FITC |
| Descripción | CD31 Monoclonal Antibody, 0.5mL, 0.2mg/mL Concentration, MBC78.2 Clone, CD31 Antigen, Human CD31 Immunogen, Mouse Host, Human Species Reactivity, FITC Conjugate, IgG1 Isotype, PBS + BSA Storage Buffer, Used for Flow Cytometry |
| Dilución | Assay-dependent |
| Formulación | PBS with 4mg/mL BSA and 0.1% sodium azide |
| génica | Pecam1 |
| Mostrar más |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?